Reacción de hipersensibilidad a carboplatino no reversible mediante protocolo de desensibilización

Authors

  • Felix Gómez de Rueda UGC Farmacia, H.G.U. Jerez de la Frontera, Spain
  • María Mar Gordon Santiago UGC Oncología Médica del HGU de Jerez (Cádiz), Spain
  • María Eugenia Tena Sempere Servicio de Oftalmología. H.S.J.D Aljarafe, Sevilla, Spain

Keywords:

Carboplatin, Hypersensitivity, Ovarian cancer

Abstract

Platinum compounds are widely used in different tumors, being carboplatin indicated in ovarian carcinoma. The main carboplatin-dose limiting toxicity is the thrombocytopenia, however, sometimes we have seen hypersensitivity reactions that, although it is not a fact too often (8-16%), can be severe. For this reason, desensitization protocols have been developed.

We report the case of a patient intervened surgically from a papillary serous carcinoma of ovary (stage IIIC) and who later received adjuvant chemotherapy with carboplatin and paclitaxel. After twenty-two months of disease-free interval, she showed unresectable abdominal relapse, so it was again treated with carboplatin and paclitaxel. During the administration of the second cycle, said severe hypersensitivity reaction to carboplatin.

Attempted to desensitization unsuccessfully, can not continue with this treatment scheme and forcing to start second line with trabectedin and pegylated liposomal adriamycin.

Downloads

Download data is not yet available.

References

Gerson R, Serrano A, Flores F, Villalobos A. Reacción de hipersensibilidad asociada a carboplatino. Anales Médicos 2003; 48 (3): 137-141.

Sánchez-Muñoz A, Mendiola C, Poza P, Canto G, Bezares S, Cortés-Funes H. Hipersensibilidad a carboplatino y paclitaxel: revisión y recomendaciones clínicas. Rev Oncol 2002; 4 (2): 68-71.

Confino-Cohen R, Fishman A, Alttaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin. Cancer 2005; 3: 640-643.

Cortijo-Cascajares S, Jiménez-Cerezo MJ, Herreros de Tejada A. Revisión de las reacciones de hipersensibilidad a antineoplásicos. Farmacia Hospitalaria 2012; 36: 148-58.

Capilla E, Casado G, Hernández S, Sierra A, Herrero A. Protocolo de desensibilización a carboplatino. A propósito de un caso. 2009. 54 Congreso Nacional de la SEFH.

Downloads

Published

2015-03-20

How to Cite

1.
Gómez de Rueda F, Gordon Santiago MM, Tena Sempere ME. Reacción de hipersensibilidad a carboplatino no reversible mediante protocolo de desensibilización. Ars Pharm [Internet]. 2015 Mar. 20 [cited 2024 Jul. 22];56(1):32-5. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4261

Issue

Vol. 56 No. 1 (2015)

Section

Clinical Notes

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).